A Phase II Study to Evaluate the Role of Weekly Cisplatin With Oral Etoposide in Ewing's Sarcoma and Primitive Neuroectodermal Tumor (PNET) With Bone and/or Bone Marrow Metatstatic Disease
- Determine the activity of cisplatin and etoposide in terms of response of patients with
metastatic Ewing's sarcoma or primitive neuroectodermal tumor.
- Assess the bone marrow and kidney toxicity of this regimen in these patients.
OUTLINE: This is a multicenter study.
Patients receive cisplatin IV over 3 hours on days 1, 8, 15, 29, 36, and 43 and oral
etoposide daily on days 1-15 and 29-43 in the absence of disease progression or unacceptable
PROJECTED ACCRUAL: A total of 21-45 patients will be accrued for this study within 2 years.
Masking: Open Label, Primary Purpose: Treatment
Ian R. Judson, MA, MD, FRCP
Institute of Cancer Research, United Kingdom
United States: Federal Government